UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 

 
FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 

 
Date of Report (Date of earliest event reported):  March 9, 2017
 

 
COGENTIX MEDICAL, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
000-20970
13-3430173
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)

5420 Feltl Road
Minnetonka, Minnesota
 
 
55343
(Address of principal executive offices)
 
(Zip Code)

(952) 426-6140
(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 


Item 2.02.
Results of Operations and Financial Condition
 
On March 9, 2017, Cogentix Medical, Inc. (the “Company”) issued a press release providing information regarding its results of operations and financial condition for the fiscal quarter and year ended December 31, 2016.
 
The Company is furnishing the information contained in this report, including Exhibit 99.1, pursuant to Item 2.02 of Form 8-K promulgated by the Securities and Exchange Commission (the “SEC”). This information shall not be deemed to be “filed” with the SEC for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01
Financial Statements and Exhibits.
 
 
(d)
Exhibits .
 
 
Exhibit No.
 
Description
 
99.1
 
Press Release of Cogentix Medical, Inc. dated March 9, 2017 (furnished herewith)
 
1

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Dated:  March 9, 2017
COGENTIX MEDICAL, INC.
       
 
By:
/s/ Brett Reynolds
 
 
Name:
Brett Reynolds
 
Title:
Sr. Vice President, Chief Financial Officer and Corporate Secretary
 
2

COGENTIX MEDICAL, INC.
CURRENT REPORT ON FORM 8-K
 
EXHIBIT INDEX
 
Exhibit No.
 
Description
 
Method of Filing
 
Press release of Cogentix Medical, Inc. dated March 9, 2017
 
Furnished herewith
 
 
3

 
Cognyte Software (NASDAQ:CGNT)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Cognyte Software Charts.
Cognyte Software (NASDAQ:CGNT)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Cognyte Software Charts.